These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12944569)

  • 21. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype.
    Izopet J; Souyris C; Sandres-Sauné K; Puissant B; Obadia M; Pasquier C; Puel J; Blancher A; Massip P
    J Med Virol; 2002 Nov; 68(3):305-10. PubMed ID: 12226815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
    Benson CA; Vaida F; Havlir DV; Downey GF; Lederman MM; Gulick RM; Glesby MJ; Wantman M; Bixby CJ; Rinehart AR; Snyder S; Wang R; Patel S; Mellors JW;
    J Infect Dis; 2006 Nov; 194(9):1309-18. PubMed ID: 17041858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD
    N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A trial of three antiretroviral regimens in HIV-1-infected children.
    Luzuriaga K; McManus M; Mofenson L; Britto P; Graham B; Sullivan JL;
    N Engl J Med; 2004 Jun; 350(24):2471-80. PubMed ID: 15190139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
    Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
    N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.
    Danner SA; Carr A; Leonard JM; Lehman LM; Gudiol F; Gonzales J; Raventos A; Rubio R; Bouza E; Pintado V
    N Engl J Med; 1995 Dec; 333(23):1528-33. PubMed ID: 7477167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort.
    Learmont JC; Geczy AF; Mills J; Ashton LJ; Raynes-Greenow CH; Garsia RJ; Dyer WB; McIntyre L; Oelrichs RB; Rhodes DI; Deacon NJ; Sullivan JS
    N Engl J Med; 1999 Jun; 340(22):1715-22. PubMed ID: 10352163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral therapy in a thousand patients with AIDS in Haiti.
    Severe P; Leger P; Charles M; Noel F; Bonhomme G; Bois G; George E; Kenel-Pierre S; Wright PF; Gulick R; Johnson WD; Pape JW; Fitzgerald DW
    N Engl J Med; 2005 Dec; 353(22):2325-34. PubMed ID: 16319381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.
    Goujard C; Bonarek M; Meyer L; Bonnet F; Chaix ML; Deveau C; Sinet M; Galimand J; Delfraissy JF; Venet A; Rouzioux C; Morlat P;
    Clin Infect Dis; 2006 Mar; 42(5):709-15. PubMed ID: 16447119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
    Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
    J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
    Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4+ count-guided interruption of antiretroviral treatment.
    ; El-Sadr WM; Lundgren J; Neaton JD; Gordin F; Abrams D; Arduino RC; Babiker A; Burman W; Clumeck N; Cohen CJ; Cohn D; Cooper D; Darbyshire J; Emery S; Fätkenheuer G; Gazzard B; Grund B; Hoy J; Klingman K; Losso M; Markowitz N; Neuhaus J; Phillips A; Rappoport C
    N Engl J Med; 2006 Nov; 355(22):2283-96. PubMed ID: 17135583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study.
    Lawrence J; Hullsiek KH; Thackeray LM; Abrams DI; Crane LR; Mayers DL; Jones MC; Saldanha JM; Schmetter BS; Baxter JD
    J Acquir Immune Defic Syndr; 2006 Oct; 43(2):169-78. PubMed ID: 16951642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee.
    Vakil NB; Schwartz SM; Buggy BP; Brummitt CF; Kherellah M; Letzer DM; Gilson IH; Jones PG
    N Engl J Med; 1996 Jan; 334(1):19-23. PubMed ID: 7494565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.